Olaf Ortmann

Landshuter Str. 65
Regensburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

Prognostic factors for lymph node infestation, long-term survival and recurrence rates in patients with vaginal cancer: a population-based study in Germany.

Prognostic factors for lymph node infestation, long-term survival and recurrence rates in patients with vaginal cancer: a population-based study in Germany.

Journal: Journal of cancer research and clinical oncology

Published: November 28, 2025

A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.

A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.

Journal: International journal of cancer

Published: June 04, 2025

Correlation of surgical volume in gynecological cancer centers with the quality of ovarian cancer care.

Correlation of surgical volume in gynecological cancer centers with the quality of ovarian cancer care.

Journal: Journal of cancer research and clinical oncology

Published: May 28, 2025

Chemotherapy in elderly patients with early breast cancer: a systematic review.

Chemotherapy in elderly patients with early breast cancer: a systematic review.

Journal: Archives of gynecology and obstetrics

Published: May 21, 2025

Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century.

Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century.

Journal: The breast journal

Published: March 18, 2025

Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.

Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.

Journal: Journal of cancer research and clinical oncology

Published: March 03, 2025

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.

Journal: BMC cancer

Published: February 21, 2025

Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen).

Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen).

Journal: Journal of ovarian research

Published: February 05, 2025

Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy.

Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy.

Journal: Cancer cell international

Published: January 14, 2025

Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer.

Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer.

Journal: International journal of molecular sciences

Published: November 27, 2024

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

Journal: Journal of cancer research and clinical oncology

Published: July 31, 2024

HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice.

HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice.

Journal: International journal of molecular sciences

Published: May 27, 2024

Showing 1-12 of 184

Last Updated: 09/26/2026